Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Myositis
•
Dermatomyositis
•
Malignancy
How do you manage dermatomyositis related to underlying malignancy?
Is there a role of immunosuppression or treating underlying malignancy will be enough?
Answer from: at Academic Institution
Treat underlying malignancy with urgency Steroid + IVIG is the best treatment for dermatomyositis with active malignancy.
Sign in or Register to read more
14848
Related Questions
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
How do you approach a patient with proximal lower limb asymmetrical weakness and pain of thighs, MRI findings of muscle enhancement of bilateral thighs but muscle biopsy with vasculitis changes only without findings of myositis.
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you utilize tools such as MMT8 in clinical practice when evaluating myositis?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
How do you approach new-onset idiopathic intracranial hypertension (IIH) with someone who has history of systemic lupus erythematosus?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
Have you utilized JAK inhibitors in patients on dialysis?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?